Binding of β 2 -glycoprotein I (β 2 -GPI)-dependent anticardiolipin antibodies (aCL) derived from antiphospholipid syndrome (APS) is significantly reduced in aCL ELISA due to loss of the phospholipid (PL) binding property of β 2 -GPI by plasmin treatment. In the present study, the treatment generated a nicked form of β 2 -GPI and resulted in loss of antigenicity for the autoantibodies detected in ELISA, using an β 2 -GPI directly adsorbed polyoxygenated carboxylated plate, the assay system of which was not related to PL binding. The nicked form bound to neither Cu 2⍣ -oxidized low-density lipoprotein (oxLDL) nor to β 2 -GPI-specific lipid ligands isolated from oxLDL, the result being a complete loss of subsequent binding of anti-β 2 -GPI autoantibodies. The conformational change in the nicked domain V was predicted from its intact structure determined by an X-ray analysis (implemented in Protein Data Bank: 1C1Z), molecular modeling and epitope mapping of a monoclonal anti-β 2 -GPI antibody, i.e. Cof-18, which recognizes the related structure. The analysis revealed that novel hydrophobic and electrostatic interactions appeared in domain V after the cleavage, thereby affecting the PL binding of β 2 -GPI. Such a conformational change may have important implications for exposure of cryptic epitopes located in the domains such as domain IV.
Introduction
Antiphospholipid syndrome (APS) is characterized by the predominant clinical features of venous and/or arterial thrombosis, recurrent pregnancy loss, and thrombocytopenia, accompanied by autoantibodies, i.e. antiphospholipid antibodies (aPL) (1) (2) (3) (4) . In 1990, three individual research groups, including ours, first reported that a 50 kDa plasma cofactor is required for cardiolipin (CL) binding of anticardiolipin antibodies (aCL) found in APS patients (5) (6) (7) . In recent years, β 2 -glycoprotein I (β 2 -GPI), which binds to anionic phospholipids (PL), is thought to be the major antigen for aCL. We also reported that epitopes for such aCL are cryptic and that they appear in domain IV of β 2 -GPI only when β 2 -into five contiguous homologous 'sushi' domains, which correspond to the short consensus repeat (SCR) of the complement control protein superfamily. Each domain has two disulfide bridges but domain V diverges from the SCR module as it has an additional disulfide bridge and a long C-terminal loop (14, 16) . The crystal structure of human β 2 -GPI was recently reported (17, 18) . Domain V of β 2 -GPI has a potent PL binding region and a structure consisting of a particular region, K 282 NKEKK 287 , was identified using synthesized peptides and mutant proteins of β 2 -GPI (19) (20) (21) (22) (23) . X-ray analysis on β 2 -GPI (17) showed that the PL binding is provided by a patch consisting of 14 residues of positively charged amino acids on the aberrant half of domain V and by a flexible loop of S 311 -K 317 . Sequential bindings of β 2 -GPI to PL such as CL and of β 2 -GPI-dependent aCL are significantly reduced by cleavage of the peptide bond between K 317 and T 318 on the C-terminal loop (20, 21) . Either factor Xa or plasmin specifically cleaves the site (24, 25) . β 2 -GPI affects multiple PL-dependent coagulation pathways but also lipoprotein metabolism (26) , and clearance of 'nonself' particles and senescent/apoptotic cells (27) (28) (29) . Previous in vitro studies also suggested that β 2 -GPI mediates activation of platelets (30) and endothelial cells (31) by aPL. An early event in atherosclerosis is the accumulation of cholesterolladen foam cells, which originate mainly from monocyte macrophage cells (32) (33) (34) , by their uptake of chemically modified low-density lipoprotein (LDL), such as Cu 2ϩ -oxidized LDL (oxLDL) (35, 36) . We reported that β 2 -GPI directly binds to oxLDL, and that the complex of oxLDL and β 2 -GPI is subsequently recognized by anti-β 2 -GPI autoantibodies to be taken up by macrophages (37) . Romero et al. reported that development of arterial thrombosis is associated with anti-β 2 -GPI antibodies but not with anti-oxLDL antibodies in systemic lupus erythematosus and the secondary APS (38) .
In the present study, we found that β 2 -GPI treatment with plasmin reduced its antigenicity detected in antibody ELISA when we used a β 2 -GPI adsorbed polyoxygenated (carboxylated) plate or using an oxLDL-derived antigen-adsorbed plain plate. Further, these reductions were accompanied by a particular conformational change in domain V.
Methods

Microtiter plates
Plain (Sumilon S-type) and polyoxygenated (carboxylated, Sumilon C-type) polystyrene plates were obtained from Sumitomo Bakelite (Tokyo, Japan). Density of oxygen atoms covalently introduced onto their surfaces was analyzed as follows: the plain plate, C-O, 1.3 mol%; and the polyoxygenated plate, C-O, 10.5 mol%, CϭO, 5.6 mol%, and O-CϭO, 3.7 mol% (9). Another plate (Immulon IIHB) was obtained from Dynex Technologies (Chantilly, VA).
Sera and mAb
β 2 -GPI-dependent aCL ϩ sera were obtained from secondary APS patients with systemic lupus erythematosus. Two human monoclonal aCL, i.e. EY1C8 and EY2C9 (anti-β 2 -GPI antibodies), originated from an APS patient (39) . Mouse monoclonal anti-human β 2 -GPI antibodies were prepared from splenocytes of BALB/c mice immunized with human β 2 -GPI in complete Freund's adjuvant (40, 41) .
Human β 2 -GPI and domain V β 2 -GPI was purified from normal human plasma by sequential CL-affinity column, ion-exchange column and Protein ASepharose column chromatography (8) . A recombinant domain V protein was expressed in methylotrophic yeast, Pichia pastoris and was purified (23) .
Treatment with plasmin β 2 -GPI (2 mg) and domain V (0.5 mg) were treated with human plasmin (Calbiochem-Novabiochem, La Jolla, CA) in 2 ml of PBS at 37°C for 3 h. The reaction was performed at a molar ratio of plasmin:substrate of 1:3.2 and was terminated by adding 3 mg of aprotinin. The nicked samples were subsequently purified by affinity chromatography, using anti-β 2 -GPI-and heparin-Sepharose columns and by an ionexchange chromatography, using a Mono-Q column (Pharmacia-Biotech, Uppsala, Sweden).
SDS-PAGE and immunoblot
Reduced samples were subjected to 12 or 16.5% SDS-PAGE, according to Laemmli (42) . Proteins were transferred onto a nitrocellulose sheet and the sheet was blocked by incubation with 10 mM Tris-HCl/150 mM NaCl, pH 7.4, containing 0.05% Tween (TBS/Tween) and 3% skim milk. Following incubation with anti-β 2 -GPI antibodies in TBS/Tween, the sheet was exposed to horseradish peroxidase (HRP)-labeled anti-mouse IgG antibodies and then to 4-chloro-1-naphthol with H 2 O 2 . Between each step, extensive washings were done using TBS/Tween.
Anti-β 2 -GPI ELISA
Anti-β 2 -GPI ELISA was performed as described (9) . Briefly, β 2 -GPI or domain V was adsorbed on a plain (Sumilon S-type) or polyoxygenated (carboxylated, Sumilon C-type) plate by incubating at 10 µg/ml (50 µl/well). The plates were blocked with 3% gelatin and 100 µl/well of anti-β 2 -GPI mAb (1 µg/ml) or of 100-fold diluted serum samples were applied for 1 h. Antibody binding to β 2 -GPI was probed using HRPlabeled anti-mouse IgG antibodies or HRP-labeled anti-human IgG/IgM antibodies. o-Phenylenediamine solution containing H 2 O 2 was applied. The color reaction was stopped by adding 2 N H 2 SO 4 . Optical density was measured at 492 nm. Between each step, we used PBS containing 0.05% Tween 20 (PBS/ Tween) for extensive washings.
Competitive assay for β 2 -GPI binding to solid-phase CL CL (2.5 µg in 50 µl of ethanol/well) was adsorbed by evaporation on a plain plate. The plate was blocked with 1% BSA and then biotinyl-β 2 -GPI was incubated with the indicated concentrations of mouse anti-β 2 -GPI mAb in the CL plates for 1 h. β 2 -GPI binding was detected using HRP-labeled avidin. Further steps were as described in 'Anti-β 2 -GPI ELISA'.
Preparation of oxLDL-and β 2 -GPI-specific ligands
LDL, prepared by ultracentrifugation of normal human plasmas, was oxidized by incubation with CuSO 4 , as described (37) . To isolate ligands specific for β 2 -GPI from oxLDL preparation, lipid extraction (43) , and silica-gel TLC (Kiesegel 60, Merck, Darmstadt, Germany; solvent (i): chloroform/methanol/H 2 O/NH 4 OH: 60/40/5/2.5 and solvent (ii): chloroform/methanol: 8/1) and reversed-phase HPLC on Sephasil peptide C18 (Pharmacia-Biotech, Uppsala, Sweden) (solvent: acetonitrile/ isopropanol: 30/70) were subsequently done. The β 2 -GPI-specific ligands were monitored by a ligand blot analysis using β 2 -GPI, anti-β 2 -GPI mAb (Cof-22 and EY2C9) and HRP-labeled anti-mouse IgG antibodies/antihuman IgM antibodies. These ligands were characterized as oxidative products of ketocholesteryl-linoleate (submitted).
Assay for β 2 -GPI binding to oxLDL F(ab)Ј 2 of anti-apoB100 mAb, i.e. 1D2 mAb, was adsorbed on a microtiter plate (Immulon IIHB) by incubating with 5 µg/ml (50 µl/well). The plate was blocked with 1% skim milk, followed by incubating with 10 µg/ml of native LDL or Cu 2ϩ -oxLDL for 1 h. Then, β 2 -GPI (10 µg/ml), Cof-22 (1 µg/ml) and HRP-labeled anti-mouse IgG antibodies were subsequently incubated for each 1 h. Further steps were as described under methods for 'Anti-β 2 -GPI ELISA'.
Assay for β 2 -GPI and antibody binding to β 2 -GPI-specific ligands β 2 -GPI-specific ligands (1.25 µg in 50 µl of ethanol/well) were adsorbed by evaporation on a plain plate and the plate was then blocked with 1% BSA. For detection of β 2 -GPI binding, β 2 -GPI (15 µg/ml), anti-β 2 -GPI antibody (Cof-22, 1 µg/ml) and HRP-labeled anti-mouse IgG antibodies were subsequently incubated. For detection of antibody binding, intact or the nicked β 2 -GPI or domain V (15 µg/ml), anti-β 2 -GPI mAb (1 µg/ml) or 100-fold diluted serum samples, and HRP-labeled anti-human IgG or IgM antibodies were subsequently incubated. Further steps were as described under methods for 'Anti-β 2 -GPI ELISA'.
Construction and optimization of the nicked domain V' s conformation
A possible conformation of the nicked domain V was constructed from its intact structure determined by an X-ray analysis (implemented in Protein Data Bank: 1C1Z), based on molecular modeling. According to the high thermal factors of residues of S 311 -W 316 , and the presence of a hydrophobic hole composed of F 279 , F 280 and F 307 , we predicted a possibly hydrophobic interaction between a region F 315 -W 316 and the hole in the nicked β 2 -GPI. An initial model was created by following two processes using Quanta 97 (Molecular Simulations, San Diego, CA): (i) cleavage of the peptide bond of K 317 -T 318 , and (ii) closing the distance in 5Å between the side chains of amino acids related to the interaction described above.
The initial model was then optimized by 2000 cycles of energy minimization by the CHARMm program (44) , with hydrophilic hydrogen atoms and TIP3 water molecules (45) in 8Å radius around the protein, adopting the standard amino acid parameters in the CHARMm force field. Molecular dynamics simulation (5 ps) of the model was then performed with 0.002 ps time steps. Cut-off distance for non-bonded interactions was set to 15Å and the dielectric constant was 1.0 when calculating the electrostatic energy. A non-bonded pair list was updated every 10 steps. Finally, the model was again optimized by 2000 cycles of energy minimization. The nicked domain V consisted of 82 amino acid residues (811 protein atoms) with 585 water molecules and had a total energy of -1.64ϫ10 4 kcal/mol, and averaged root-meansquare forces 0.355. For purposes of comparison with the nicked model, optimization and dynamics simulation were also performed in the case of the original X-ray structure of intact domain V. The optimized structures of intact and the nicked structures had a total energy of -3.86 ϫ10 3 and -4.11ϫ10 3 kcal/mol, under conditions where water molecules were omitted respectively.
Epitope mapping
Epitope mapping of Cof-18 mAb was performed by using a combinatorial library of a 12mer random peptide fused with a minor coat protein (pIII) of the filamentous coliphage, M13 (PH.D-12 Kit, New England Biolabs, Beverly, MA). A plain plate was coated with Cof-18 mAb (100 µg/ml) and blocked with 5 mg/ml of BSA. Phages (2ϫ10 12 / ml) were incubated for 1 h and the bound phages were eluted with 0.2 M glycineHCl (pH 2.2). After three rounds of the biopanning, the specific phages were cloned and sequenced.
Results
Proteolytic cleavage of human β 2 -GPI β 2 -GPI nicked at the site between K 317 and T 318 was generated by a limiting enzymatic cleavage with plasmin. Almost complete cleavage (Ͼ98%) occurred in both β 2 -GPI and domain V by treatment at 37°C for 3 h (Fig. 1A) .
Features of anti-β 2 -GPI mAb
We previously established mouse anti-β 2 -GPI mAb (i.e. Cof-18, -20, -21, -22 and -23), and determined that their epitopes to locate in domains V, III, IV, III, and IV, respectively (40, 41) . Immunoblot analysis showed that four mAb, i.e. Cof-20, -21, -22 and -23, reacted with both intact and the nicked β 2 -GPI proteins but not with any domain V proteins (Fig. 1B) , because their epitopes are present in domain III or IV. In contrast, Cof-18 mAb bound to intact β 2 -GPI and domain V but not to their nicked forms. Three antibodies, i.e. Cof-20, -21 and -22, revealed almost equal binding to intact and the nicked β 2 -GPIs when adsorbed on either a plain or a polyoxygenated plate (Fig. 2) . In ELISA using β 2 -GPI-adsorbed plates, binding of Cof-18 (specific to domain V) and Cof-23 (to domain IV) was affected by treatment of β 2 -GPI with plasmin. In particular, Cof-18 binding to the nicked β 2 -GPI adsorbed on those plates was diminished.
As shown in Fig. 3 , Cof-18 mAb inhibited the β 2 -GPI binding to solid-phase CL in a dose-dependent manner. Thus, Cof-18 mAb competitively affected PL binding of β 2 -GPI. The specificity of Cof-18 was confirmed using other irrelevant Cof mAb. In contrast, Cof-18 mAb inhibited the plasmin-mediated cleavage in domain V (Fig. 4) . Other irrelevant Cof antibodies or an anti-β 2 -GPI autoantibody, EY2C9, did not affect the cleavage (data not shown). 
Features of autoimmune anti-β 2 -GPI antibodies
In ELISA using a polyoxygenated carboxylated plate, anti-β 2 -GPI mAb, EY1C8 and EY2C9, and antibodies in all tested anti-β 2 -GPI ϩ sera (n ϭ 30) bound only to intact β 2 -GPI but not to the nicked one (Fig. 5) . No antibodies in the APS sera bound to either forms of domain V.
Specific binding of β 2 -GPI to oxLDL and to the ligand derived from oxLDL was completely lost by plasmin treatment (Fig. 6A-C) . Subsequent binding of anti-β 2 -GPI antibodies derived from APS patients was diminished due to lack of the nicked β 2 -GPI binding to the solid-phase ligands (Fig. 6D) . 
Structure of the nicked domain V
We predicted the conformation of nicked domain V from the X-ray structure of the intact domain (Fig. 7) . In intact domain V, a hydrophobic hole, consisting of F 279 , F 280 and F 307 , was hidden by the C-terminal region, T 318 -K 324 , and another hydrophobic region, F 315 and W 316 , was exposed to the solvent (Fig. 8) . The nicked structure was constructed by considering interactions between these two hydrophobic regions and optimized with the solvent phase. The nicked structure was more stable than the intact one (total 6 . β 2 -GPI and subsequent anti-β 2 -GPI autoantibody binding to LDL and the β 2 -GPI-specific ligand derived from oxLDL. Native LDL (A) or oxLDL (B) was incubated in an anti-apoB100 F(ab)Ј 2 -adsorbed plain plate. The β 2 -GPI-specific ligand (C) was directly adsorbed on a plain plate. Intact or nicked β 2 -GPI binding was detected with anti-β 2 -GPI mAb (Cof-22) and HRP-labeled anti-mouse IgG antibodies. (D) Intact or nicked β 2 -GPI or domain V antibodies and HRP-labeled anti-human IgG or IgM antibodies were subsequently incubated in a β 2 -GPI-specific ligand-adsorbed plain plate to detect autoantibody binding.
energy -3.86ϫ10 3 kcal/mol for intact domain V and -4.11ϫ 10 3 kcal/mol for the nicked one).
In the nicked structure, the side chains of F 315 and W 316 oriented to the hydrophobic hole, and those of D 319 and D 322 , containing in the C-terminal loop (colored orange), were tightly fixed by electrostatic interaction with R 260 . Positive charges of K 317 and K 250 were weak due to their interaction with E 265 and E 309 respectively. Positive charges of five residues, i.e., K 250 , R 260 , K 262 , K 284 and K 324 , on the patch (17) were neutralized by interactions with carboxyl groups of E 309 , D 319 /D 322 , K 317 (on the main chain), E 285 and C 326 (on the main chain) respectively. Further, the patch was dislocated by the relocation of D 319 and D 322 .
Epitopic structure for Cof-18 mAb
As an approach to characterize the conformational change which occurred in domain V, we analyzed the epitopic struc- ture recognized by Cof-18 mAb because the mAb recognized a structure related to both PL binding and plasmin-mediated cleavage. Phage clones carried the consensus sequence GMKLTSEQKAML and SDWRLMFESWIR (Table 1 ). The amino acid sequence SE*K, located downstream of the first consensus sequence, was closely related to the sequence SD*R located upstream of the second ones. The suggested corresponding amino acid residues from these two consensus sequences are shown in the intact structure (Fig. 9A) . A cluster composed of these amino acid residues for the epitopic structure located across three discontinuous loops. We synthesized a 16mer peptide, i.e. pCof-18, which was basically designed from these two consensus sequences and several 12 mer scrambled control peptides. Binding of phage #1 to the solid-phase Cof-18 mAb was stoichiometrically evident by analysis using the IAsys optical biosensor (Fig.  10A) . Phage binding to Cof-18 mAb was dose-dependently inhibited by the simultaneous addition of pCof-18 (Fig. 10B) . The binding was not affected by any control peptides tested in the system. The inhibitory effect of β 2 -GPI on phage binding to Cof-18 antibody was observed in ELISA, using the solidphase phage #1 (Fig. 10C) . The structural analysis indicated that the cluster of amino acids which formed a Cof-18's epitope stretched after the cleavage (Fig. 9B) .
Discussion
In 1994, we demonstrated that anti-β 2 -GPI autoantibodies bind to β 2 -GPI adsorbed on a polyoxygenated but not on a plain plate and also considered that those epitopes are probably cryptic (9). Later, it was shown that domain IV is dominantly involved in expression of such epitopes, determined using a series of deletion mutants of β 2 -GPI (40) . So far as tested in the present study, anti-β 2 -GPI autoantibodies did not bind directly to any solid-phase domain V (Fig. 5) . By epitope mapping and structural analysis, we identified fine structures of those epitopes located in domain IV (submitted). Thus, it is most likely that anti-β 2 -GPI autoantibodies recognize cryptic epitopes located in domain IV. In the present study, we showed that β 2 -GPI treatment with plasmin reduced expression of the epitopes and the reduction was accompanied by a particular conformational change in domain V.
It was reported that binding of aCL from sera of APS patients in ELISA using a CL-adsorbed plate was diminished due to the loss of PL binding by the plasmin-mediated cleavage of β 2 -GPI (20) . Human and mouse anti-β 2 -GPI autoantibodies did not bind to the nicked β 2 -GPI in an anti-β 2 -GPI ELISA when we used a polyoxygenated carboxylated plate, on which antigen proteins were directly adsorbed but (1) 2.6ϫ10 8 , (2) 6.5ϫ10 8 , (3) 1.3ϫ10 9 , (4) 2.6ϫ10 9 and (5) 5.2ϫ10 9 /ml of cloned phage #1 were added to the cuvette and phage binding was measured using an optical biosensor, IAsys. Plots of measured on-rate constant (k on ) for concentrations of phage are also indicated. (B) Inhibitory effect of pCof-18 on phage #1 binding to solid-phase Cof-18 mAb was assayed by the IAsys. (C) Inhibitory effect of β 2 -GPI on Cof-18 mAb binding to the solidphase phage #1 was assayed using ELISA. Indicated concentrations of β 2 -GPI and Cof-18 mAb were incubated in the phage #1-adsorbed plate (by previously incubating with 6ϫ10 11 /well) for 1 h and antibody binding was then measured with HRP-labeled anti-mouse IgG antibodies.
not so with any PL (Fig. 5) . In contrast, β 2 -GPI binding of irrelevant mouse anti-human β 2 -GPI mAb was equal to its nicked form adsorbed either on a plain or polyoxygenated plate. These observations imply that proteolytic cleavage does not simply reduce PL binding but it also prevents exposure of the cryptic epitopes.
Conformational changes occurring with the cleavage were analyzed by constructing the nicked structure. A hydrophobic region, F 315 -W 316 , originating in the flexible C-terminal loop (17) possibly interacted with another hydrophobic hole consisting of F 279 , F 280 and F 307 , the result being reduced positive charges on the patch and dislocation of the patch (Fig. 8) . The epitope of Cof-18 mAb located in close proximity in the cleaved region and the positively charged patch was stretched in the nicked β 2 -GPI (Fig. 9) . Thus, the structural analysis of the nicked domain V indicates a possible relationship between the plasmin-mediated cleavage and the loss of the PL binding.
Against an 'elongated' crystal structure of β 2 -GPI, (17,18), we constructed an alternative model, in which three electrostatic interactions, i.e. D 193 -K 246 , D 222 -K 305 and E 228 -K 308 , were observed between domain IV and V (submitted). We also found in the study that binding of anti-β 2 -GPI autoantibodies was significantly reduced by replacement of these three acidic amino acids in domain IV by valines (V). These observations also supported the notion that the conformational change in domain V may affect exposure of the cryptic epitopes in domain IV.
In contrast, Iverson et al. (46) reported mainly detecting autoantibodies directed to an intact structure of domain I, in ELISA using deletion mutants proteins similar to those we had previously designed (40) . A lysine-enriched patch for PL binding was found to locate on a surface of domain V (17) . It is generally thought that β 2 -GPI is adsorbed on a CL-plain polystyrene plate, via both hydrophobic and electrostatic interactions to express antigenicity for aCL. However, their mutant proteins were stretched on the nickel chelate-coated plate via their extra C-terminal glycine (G)-histidine (H) six residues but neither via the PL binding region nor by hydrophobic protein adsorption. We are entertaining the notion that both the orientation of adsorbed β 2 -GPI and direct adsorption via the PL binding region might be essential for expression of such cryptic epitopes, even in anti-β 2 -GPI ELISA using a polyoxygenated plate.
Numerous in vitro studies showed that β 2 -GPI acts as a natural anti-coagulant protein and that autoimmune abnormalities accompanied by the induction of anti-β 2 -GPI autoantibodies may lead to a pathological stage, i.e. athero-thrombosis. We also reported that subsequent binding of β 2 -GPI and anti-β 2 -GPI autoantibodies directed to oxLDL enhanced oxLDL uptake by macrophages (37) . Further, several in vivo studies attractively demonstrated pathogenesis of anti-β 2 -GPI antibodies, i.e. immunization with β 2 -GPI-induced autoantibodies in mice and rabbits (47) , induced APS-like syndrome (48) , and accelerated atherosclerosis in mice (49) . The present study showed that β 2 -GPI binding and subsequent binding of anti-β 2 -GPI autoantibodies either to oxLDL or to the β 2 -GPI-specific ligands from oxLDL were lost by plasmin treatment (Fig. 5) . It is likely that the plasmin-mediated cleavage has important implications for down-regulation of 'autoimmune' athero-thrombosis in APS.
One possible hypothesis that has been advocated is that anti-β 2 -GPI autoantibodies probably prevented natural anticoagulant activity of β 2 -GPI that affects the PL-dependent coagulation cascades and it results in the thrombotic events developing. Brighton et al. first found that β 2 -GPI levels in plasma were significantly low in patients with thrombosis or disseminated intravascular coagulation syndrome (DIC) (50). Horbach et al. recently reported that plasma β 2 -GPI levels were lower in patients with DIC as compared with controls and nicked β 2 -GPI levels were contrarily high (51) . They suggested that the reduction of β 2 -GPI levels and the generation of nicked β 2 -GPI occurred due to absorption to apoptotic cells and activation of fibrinolysis respectively. Kato et al. reported that the nicked form of β 2 -GPI was generated either by factor Xa or by plasmin, but the latter was much more effective (24, 25) , and that an increment of serum nicked β 2 -GPI was observed in APS patients (52) . Thus, the cleavage of β 2 -GPI by the multiple cascades on blood coagulation or fibrinolysis, which leads its reduced antigenicity, may play a role in a natural self-defense against the autoimmunity to develop thrombosis in APS. The clinical significance of the nicked β 2 -GPI should be elucidated in future studies.
